Tummarello D, Porfiri E, Guidi F, Isidori P, Raspugli M, Biscottini B, Fatati G, Cellerino R
Clinica Oncologica dell'Università di Ancona, Italy.
Tumori. 1989 Oct 31;75(5):486-8. doi: 10.1177/030089168907500518.
Sixty-eight evaluable patients with advanced squamous cell carcinoma (48), large cell carcinoma (2) and adenocarcinoma (18) of the lung were treated with a six-drug regimen delivering two monthly alternated combinations. The combinations were cisplatin, adriamycin and cyclophosphamide (CAP) and methotrexate, etoposide and CCNU (MEC'). Following a minimum of two courses, the overall response rate was 22% (confidence limits, 12% to 32%) (15/68, 2 complete responses and 13 partial responses); 47% (32/68) had stable disease and 31% (21/68) had progressive disease. The responses lasted a median of 3 months (range, 1-15 months). The actuarial median survival was 11 months in responsive patients, 10 months in stable disease patients, and 5 months in progressive patients. The overall median survival obtained was 9 months (range, 2-28+ months). Toxicity was minimal, and subjective tolerance of the treatment appeared good. However, this alternating program did not improve response rate or survival.
68例可评估的晚期肺癌患者（其中鳞状细胞癌48例、大细胞癌2例、腺癌18例）接受了一种六药方案治疗，该方案每两个月交替使用两种联合用药。联合用药分别是顺铂、阿霉素和环磷酰胺（CAP）以及甲氨蝶呤、依托泊苷和洛莫司汀（MEC'）。至少经过两个疗程后，总缓解率为22%（置信区间为12%至32%）（68例中有15例缓解，2例完全缓解，13例部分缓解）；47%（32/68）的患者疾病稳定，31%（21/68）的患者疾病进展。缓解持续时间的中位数为3个月（范围为1至15个月）。缓解患者的精算中位生存期为11个月，疾病稳定患者为10个月，疾病进展患者为5个月。总体获得的中位生存期为9个月（范围为2至28+个月）。毒性极小，治疗的主观耐受性似乎良好。然而，这种交替方案并未提高缓解率或生存期。
